Dr. Eleanor Carter Facebook ad: “Ceylon Cinnamon 7200mg Equivalent with MCT Oil”

About this ad

Meta Ad Library ID

956345120838924

Platforms

Facebook, Instagram, Audience Network and Threads

Relaunches

1

Niche

Supplements & Wellness

How we count

Ad text

My older sister had Type 2 diabetes. She died of her second heart attack 9 months ago. She was 59. She was a nurse too. Same meds. Same blood pressure her cardiologist kept calling managed. Same arterial readings he was keeping an eye on. After the funeral, I went looking for what actually killed her. What I found is that her blood pressure medication was doing exactly what it was designed to do. And it still wasn't the whole picture. Her name was Carol. She worked labor and delivery for thirty-one years at Mercy General. Two daughters. A husband named Pete who still left her a note on the kitchen counter every morning before he left for work. She ran a 10K every fall until she was fifty-three. She taught every new nurse on her unit how to read a fetal monitor before the attending could blink. She baked banana bread for the floor on holidays and remembered every staff member's birthday without writing it down. She was the one you called at midnight when you had a patient crashing and needed someone who had seen it before. She was 59 years old. She should still be here. Carol got her Type 2 diagnosis at fifty-one. Her primary care doctor put her on Metformin. Her A1C came down from 8.1 to 7.3 in the first year. Well-managed, the doctor called it. Said they'd keep an eye on things. By fifty-two her blood pressure was climbing. Her cardiologist put her on Lisinopril. Said her arterial readings were borderline. Said they'd watch it closely. Her LDL was elevated, so a statin went onto the list. For six years Carol went to every appointment. Took every medication. Had her blood drawn every quarter. Checked her blood pressure at the pharmacy kiosk on her way out after every shift. Her cardiologist told her the same thing after every visit. Numbers look good, Carol. Keep doing what you're doing. Her blood pressure reading at her last appointment was 126 over 74. Six days later she had her second heart attack. She did not come home from it. The doctor who came to find Pete in the family room afterward said something I have heard versions of too many times in my own unit. She was well-managed. These things happen. I'm so sorry for your loss. There was a list stuck to Carol's refrigerator when Pete's daughters came to help him clear out the kitchen. She had written up her grocery run for the week. Picked a date for the granddaughter's birthday party at the park. Left a reminder to call the roofer on Tuesday. She was not planning to die. Her numbers looked fine. I am Sandra Keller. I have been an ICU nurse for 27 years. I have held the hands of patients who did not make it back to their families. I have stood in the room when a doctor walks out to find a spouse, and I have watched that spouse try to hold on to what the doctor is saying while their whole life is becoming something else. I have seen the trajectory from every angle this work offers. So when my own A1C came back at 6.8 at my annual physical and my doctor looked at my blood pressure log and said we probably need to start something, I knew what came next before she finished the sentence. Lisinopril. And let's look at a statin. I smiled. Nodded. Filled both prescriptions on the way home. And sat in the pharmacy parking lot for a long time before I started the car. Because I was in my mid-fifties. And I had the same blood pressure readings Carol had when her cardiologist called hers borderline. The same A1C her doctor called well-managed. The same trajectory. I drove home and did not say what I was thinking out loud to my husband. Two weeks after Carol's funeral I could not sleep. I had been lying awake most nights since the service, going over the same words her cardiologist had said in the hallway. Well-managed. These things happen. Carol was a nurse. She understood her medications better than most of her patients understood theirs. She went to every appointment. She never missed a dose. She monitored her blood pressure with more clinical attention than people who had not spent three decades at a bedside. And her arteries still took damage anyway. That told me there was a piece of this her medications weren't reaching. And I needed to understand what it was. At 2 in the morning I got up, went to the kitchen, and opened my laptop. My daughter is a pharmacist. She keeps late hours. I texted her: if I send you papers tonight, can we go through them tomorrow. She called me back in four minutes. She already knew about Carol. She said yes. I was not looking for a supplement. I was looking for what still gets Type 2 diabetics whose numbers looked fine at their last appointment. The first paper I found tracked cardiac events in Type 2 patients with controlled blood pressure and LDL readings over ten years. The event rate was not dramatically lower than in patients whose readings were not controlled. The numbers looked different. The outcomes barely did. The second paper examined arterial tissue postmortem in Type 2 diabetics who had died of cardiac events. The degree of damage in the arterial tissue did not match what the managed readings at their last appointments had indicated. The arteries were more damaged than the monitored numbers suggested. By 4 in the morning I had eleven papers open and three pages of notes on a legal pad. I could see the shape of something in the research. I was too tired and too close to it to trust what I thought I was reading. I called my daughter at seven and read her my notes over the phone. She was quiet for a moment. Then she laughed, a little tired. "Okay. Slow down. You're jumping to the end. Let's go one piece at a time." Every cell in your body has receptors on its surface, she said. When you eat, the pancreas releases insulin. Insulin signals those receptors to open and accept glucose from the bloodstream. Glucose moves out of the blood and into the cell, where it gets burned for energy. "But after years of the modern diet, the receptors stop responding to the signal the way they used to," she said. "Insulin knocks. The doors don't open as easily. Glucose has fewer places to go." It stays in the blood longer than it should. I told her I knew this part. Insulin resistance. We covered it in continuing education twice a year. "You know the vocabulary," she said. "I'm asking you to follow it forward instead of backward. Stay with me a second." Glucose that lingers in the blood doesn't just sit there quietly, she said. It circulates with every heartbeat. And over years, that persistent excess contributes to inflammation and stiffening in the lining of the blood vessels — a process called glycation. It's slow. It's cumulative. And it's a separate mechanism from blood pressure itself. I was writing as fast as she was talking. "The vessels that show it first are usually the smallest," she said. "The ones feeding the peripheral nerves. That's the foot tingling. Sometimes the retinal vessels. The renal vessels. Eventually, in some patients, the coronary arteries. They're larger, so damage there tends to show up later. But over enough years, the same process reaches them too." "Here's the part that took me longer to put together," she said. "Lisinopril lowers the pressure the heart has to pump against. That's real, and it matters — it reduces strain on the heart and vessels. But it isn't designed to reverse glycation damage that's already accumulating from elevated glucose. Two different problems. One medication addresses one of them." I set down my pen. Carol's blood pressure read 126 over 74 the week she died. Her blood pressure, by that measure, really was doing well. Her glucose-driven vascular damage may have been on a different timeline entirely. I asked my daughter why no one had walked Carol through this at any of her appointments. She paused. "Because a fifteen-minute visit gets built around the reading in front of the doctor and the medication that moves it. Not always the underlying process. That's not a conspiracy. It's just how the visit is structured. You've seen it from the other side of the bed." I had. I'd just never followed it all the way to Carol. Or to myself. I asked her what else, alongside the standard medications, had research behind it for the glucose-and-vessel side of the picture specifically. She told me about two compounds. The first is called MHCP. Found in true Ceylon cinnamon — Cinnamomum verum, the species native to Sri Lanka, studied in clinical settings, not the Cassia variety that fills most supplement shelves. In lab and clinical research, MHCP has been studied for its role in supporting GLUT4 receptor activity, the pathway involved in helping cells take up glucose from the bloodstream. The second compound is cinnamaldehyde. The compound that gives cinnamon its smell. It's been studied for its effect on the inner lining of blood vessels — markers of oxidative stress in the arterial wall, inflammation at sites where plaque tends to accumulate, and the flexibility of vessels that have begun to stiffen. Two compounds. One is studied for its role in glucose uptake. The other is studied at the level of the arterial wall. "That's not competing with your Lisinopril," she said. "It's a different target. Which is exactly why you don't stop taking either one." The research is there, my daughter said. The problem is most products don't deliver the compound in a form your body can actually use. She walked me through the three ways they fail. The species. Most of what's sold as "cinnamon" in a supplement is Cassia, not Ceylon. They look identical inside a capsule. Cassia contains coumarin, a compound known to burden the liver at daily doses. A Type 2 diabetic's liver is often already under more load than average. Daily Cassia adds to that load and, because it isn't the species studied, doesn't reliably deliver MHCP and cinnamaldehyde at meaningful concentrations either. I thought about every patient I had ever seen carrying a cinnamon supplement in from the drugstore. I had never known to ask what species was inside it. I had assumed cinnamon was cinnamon. The dose. The studies that showed a measurable cellular effect used a concentrated extract, not raw cinnamon powder. Concentration is what puts enough of the compound in contact with the receptor to matter. Most retail products use a fraction of what the research used — enough to legally print "Ceylon cinnamon" on the label, not enough to reach the threshold studied. If the dose is wrong, she said, the label is decoration. The delivery. MHCP and cinnamaldehyde are fat-soluble. They need a fat carrier to cross the gut lining efficiently. Dry powder in a plain capsule doesn't provide much of one. A meaningful amount of the compound can pass through the digestive tract largely unabsorbed. Three failure points. Species, dose, delivery. I asked her how many products on the market got all three right. "Not many," she said. "The right inputs cost more, so a lot of brands cut one corner or another." I spent three evenings going through every Ceylon cinnamon product I could find. Most couldn't tell me whether their cinnamon had been DNA verified at the species level. Most couldn't tell me their extraction concentration. Almost all were dry powder with no fat carrier. Then I found Metabolae. True Ceylon cinnamon. Cinnamomum verum, sourced from Sri Lanka, DNA verified at the species level. A 12 to 1 concentrated extract, dosed within the range used in the published research. Suspended in MCT oil from coconut, so the fat-soluble compounds have a carrier to help absorption. Third-party tested per batch, with the certificate available for me to check myself. Made in the USA. One softgel every morning with breakfast. That was the protocol. I ordered it that night. Week one. I kept taking my Lisinopril and my statin. I want to say that plainly. Metabolae went into my routine alongside my prescriptions, not in place of them, and I didn't change anything without talking to my doctor first. The first week was quiet. My daughter had told me to expect that. Cellular adaptation doesn't happen in 24 hours. This wasn't designed to move a cuff reading by the next morning the way a blood pressure medication can. Around day six the pressure behind my eyes when I woke up was less. I had been starting most mornings with a low, blunt tightness behind my forehead and temples. I had been attributing it to sinus pressure, to bad sleep, to whatever kept me from looking at it directly. Around day six I woke up and it wasn't there. I didn't note it yet. Could have been coincidence. Day nine it was still gone. Week two. The afternoon wall started lifting. I had been hitting a wall between 2 and 4 PM for going on two years. A heavy, slow fatigue that wasn't about sleep and that coffee didn't fix. Around day ten it started arriving later. Shorter. By day fourteen it was barely registering. My husband asked me if I was sleeping differently. I was sleeping the same hours. I was just not waking up at 3 in the morning with the tightness across my chest that I had been waking up with for the better part of a year. I had been calling it anxiety. I'm not sure now that it was. Week three. I took my blood pressure at the monitor on the unit during a quiet moment in my shift. 112 over 68. It had been sitting between 134 and 138 over 84 to 88 on Lisinopril for seven months. My doctor and I had already talked about whether the dose needed adjusting at my next visit. I took it twice more with five minutes between each reading. 112 over 70. 111 over 69. I stood at that monitor for a moment. Then I went back to work. Week four. My fasting glucose had dropped from 146 to 103 — the first time I'd seen it below 110 in two years. The tingling in both feet at night, the thing I'd been quietly attributing to long shifts on a hard floor, was gone. My husband noticed I'd stopped rubbing my feet against the sheets. Six weeks. My doctor ran a full panel. LDL down 21 points without a dose change. Triglycerides down. Blood pressure in her office: 114 over 70. She looked at the printout. Looked at me. Asked what I'd changed. I told her. She made a note of it, and we talked about whether any of my prescriptions could be adjusted going forward — a conversation we kept having at each visit after that, together. By the three-month mark my A1C was 5.9, down from 6.8. She and I agreed it was reasonable to lower my Lisinopril dose, and she wrote the new prescription herself. I brought Metabolae to five patients over the following three months. Not as a hospital recommendation. As Sandra — a nurse who had watched her sister's blood pressure read fine six days before a fatal cardiac event, who had found something worth knowing about, and who wasn't going to keep it to herself. I told each of them what I'm telling you: the mechanism, what their medications were and weren't designed to reach, the three failure points in most Ceylon supplements, and what I'd watched happen in my own labs. I also told every one of them the same thing I'm telling you now — don't change your medications on your own. Bring this to your doctor and make the call together. A 71-year-old man, recovering from a stenting procedure and on a full cardiac regimen, had been told by his cardiologist that another event was a matter of when, not if. Eight weeks in, his fasting glucose was down 42 percent from where he'd started. He brought his numbers to his cardiologist, and together they lowered his Lisinopril dose at his next follow-up. His wife called me on a Thursday evening. She said he'd walked to the mailbox and back that morning, and she'd had to go into the other room before he could see her face. A 63-year-old woman was on three blood pressure medications at once, and none of them had brought her reading fully to where her cardiologist wanted it. She'd described her morning headaches as just part of life for the past two years. Five weeks in, they stopped. She mentioned it at her twelve-week appointment, and her cardiologist moved one of the three medications to as-needed. A third patient, a 67-year-old man, had watched his resting heart rate climb alongside his blood pressure for two years, enough that his cardiologist had added a beta-blocker six months earlier. By week seven, his resting rate had come down on its own. His cardiologist ran new bloodwork and, seeing the trend hold, spaced his monitoring appointments out from quarterly to every six months. Every one of them said some version of the same thing around week three. I forgot what it felt like to feel like this. Because the decline is gradual, and that's part of why it's so easy to miss. Your blood pressure climbs by five points, the dose gets adjusted, the reading settles back, and you tell yourself it's managed. Then it climbs again. Somewhere along the way, 136 over 86 becomes the number you stop reacting to. The tightness behind your eyes becomes your normal morning. The 3 a.m. wakeup becomes just what sleep looks like now. The afternoon wall becomes something you schedule around and call getting older — because looking closer means admitting there may be a slower process still running underneath a reading that looks fine. This might not be what getting older has to feel like. It might be what years of elevated glucose circulating through the arterial wall feel like, alongside — not instead of — whatever your current medications are managing. Your Lisinopril and your statin are still doing their job. This isn't a reason to stop them. It's a reason to ask your doctor what else might be worth addressing alongside them. One softgel every morning with breakfast. That's the whole protocol. Not another prescription to add on your own initiative. Not an injection. Not a specialist referral. One softgel studied for supporting glucose uptake and arterial-wall health — the parts of this picture your current medications aren't specifically designed to reach. It's meant to work alongside your Lisinopril, not instead of it. Your medication manages blood pressure. Metabolae is aimed at a different part of the mechanism. They're not competing. Don't stop your prescriptions, and talk to your doctor before making any changes to them. 90-day money-back guarantee. Open the bag. Take it every morning for 90 days. If you don't notice a shift worth keeping, send back what's left. Full refund. Opened bags accepted. No questions asked. I couldn't get this to Carol before her reading said fine and her heart still failed. If you're reading this, there may still be time to ask a fuller question than the one your last appointment answered. Sandra Keller, RN, ICU, 27 years P.S. Counterfeit products are circulating on third-party marketplace sites using similar packaging — Cassia and cheap seed oil instead of true Ceylon and MCT oil. Cassia contains coumarin, which stresses the liver at daily doses. The only place to get the verified formula is through the official page. P.P.S. When your readings improve and your A1C comes down, don't stop. I've watched people stabilize their numbers and decide they've solved it, only to see the readings start climbing again a few months later. The adaptation that holds these results steady seems to take six to eight months of consistent daily use. Let your doctor adjust your prescriptions as the numbers improve, together with you. That's the right way to do this.

Where the ad sends people

metabolae.com

Ceylon Cinnamon 7200mg Equivalent with MCT Oil

Supports healthy blood sugar levels and metabolism with premium Ceylon cinnamon. Shop Metabolae's science-backed supplements. Free shipping available.